EP1263453A4 - Pharmazeutische formulierung bestehend aus einem polymermatrix, zur regulierung der zeitgesteuerten freisetzung von biologisch aktiven substanzen - Google Patents

Pharmazeutische formulierung bestehend aus einem polymermatrix, zur regulierung der zeitgesteuerten freisetzung von biologisch aktiven substanzen

Info

Publication number
EP1263453A4
EP1263453A4 EP01939971A EP01939971A EP1263453A4 EP 1263453 A4 EP1263453 A4 EP 1263453A4 EP 01939971 A EP01939971 A EP 01939971A EP 01939971 A EP01939971 A EP 01939971A EP 1263453 A4 EP1263453 A4 EP 1263453A4
Authority
EP
European Patent Office
Prior art keywords
regulating
biologically active
active compounds
polymer matrix
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP01939971A
Other languages
English (en)
French (fr)
Other versions
EP1263453A2 (de
Inventor
Joachim B Kohn
Deborah M Schachter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Publication of EP1263453A2 publication Critical patent/EP1263453A2/de
Publication of EP1263453A4 publication Critical patent/EP1263453A4/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP01939971A 1999-12-31 2001-01-02 Pharmazeutische formulierung bestehend aus einem polymermatrix, zur regulierung der zeitgesteuerten freisetzung von biologisch aktiven substanzen Ceased EP1263453A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17413799P 1999-12-31 1999-12-31
US174137P 1999-12-31
PCT/US2001/000030 WO2001049249A2 (en) 1999-12-31 2001-01-02 Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix

Publications (2)

Publication Number Publication Date
EP1263453A2 EP1263453A2 (de) 2002-12-11
EP1263453A4 true EP1263453A4 (de) 2008-02-20

Family

ID=22634986

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01939971A Ceased EP1263453A4 (de) 1999-12-31 2001-01-02 Pharmazeutische formulierung bestehend aus einem polymermatrix, zur regulierung der zeitgesteuerten freisetzung von biologisch aktiven substanzen

Country Status (5)

Country Link
EP (1) EP1263453A4 (de)
JP (1) JP2003519164A (de)
AU (1) AU784226B2 (de)
CA (1) CA2396037A1 (de)
WO (1) WO2001049249A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049311A1 (en) 1999-12-31 2001-07-12 Rutgers, The State University Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
PT1682537E (pt) 2003-11-05 2012-06-20 Sarcode Bioscience Inc Moduladores de adesão celular
ES2614080T3 (es) 2005-05-17 2017-05-29 Sarcode Bioscience Inc. Composiciones y métodos para el tratamiento de trastornos oculares
EP2114298B1 (de) 2006-02-08 2022-10-19 Medtronic, Inc. Vorübergehend versteifte maschenprothesen
US8315700B2 (en) 2006-02-08 2012-11-20 Tyrx, Inc. Preventing biofilm formation on implantable medical devices
US9265865B2 (en) 2006-06-30 2016-02-23 Boston Scientific Scimed, Inc. Stent having time-release indicator
MX2009004821A (es) 2006-11-06 2009-11-23 Tyrx Pharma Inc Bolsas de malla para dispositivos medicos implantables.
US9023114B2 (en) 2006-11-06 2015-05-05 Tyrx, Inc. Resorbable pouches for implantable medical devices
CA2682190C (en) 2007-03-29 2015-01-27 Tyrx Pharma, Inc. Biodegradable, polymer coverings for breast implants
EP2150119B1 (de) 2007-05-02 2018-04-11 Tyrx, Inc. Dihydroxybenzoatpolymere und ihre verwendung
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2830024T3 (es) 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010006046A1 (en) 2008-07-10 2010-01-14 Tyrx Pharma, Inc. Nsaid delivery from polyarylates
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
CA2737769C (en) 2008-09-22 2014-02-04 Arthur Schwartz Linear polyesteramides from aminophenolic esters
US9839628B2 (en) 2009-06-01 2017-12-12 Tyrx, Inc. Compositions and methods for preventing sternal wound infections
WO2010141475A1 (en) * 2009-06-01 2010-12-09 Tyrx Pharma, Inc. Compositions and methods for preventing sternal wound infections
US8415449B2 (en) * 2009-07-31 2013-04-09 Rutgers, The State University Of New Jersey Bioresorbable polymers synthesized from monomer analogs of natural metabolites
US8409279B2 (en) 2009-10-01 2013-04-02 Lipose Corporation Breast implant implantation method and apparatus
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
ES2713515T3 (es) 2010-08-25 2019-05-22 Tyrx Inc Recubrimientos novedosos para dispositivos médicos
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2011326417A1 (en) 2010-11-12 2013-05-09 Tyrx, Inc. Anchorage devices comprising an active pharmaceutical ingredient
JP2014523330A (ja) 2011-07-20 2014-09-11 タイレックス・インコーポレイテッド 留置型経皮的デバイスの感染を予防するための薬物溶出メッシュ
JP6607780B2 (ja) 2012-07-25 2019-11-20 サルコード・バイオサイエンス・インコーポレイテッド Ｌｆａ−１阻害剤およびその多形
AU2014218599C1 (en) 2013-02-25 2018-09-06 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for use in colonic cleansing
WO2014137454A1 (en) 2013-03-07 2014-09-12 Tyrx, Inc. Methods and compositions to inhibit the assemblage of microbial cells irreversibly associated with surfaces of medical devices
EP2970384A1 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonisten der guanylatcyclase und deren verwendungen
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
MY176976A (en) 2013-10-10 2020-08-28 Bausch Health Ireland Ltd Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
EP3065788A1 (de) 2013-11-08 2016-09-14 Tyrx, Inc. Antimikrobielle zusammensetzungen und verfahren zur verhütung von infektionen in chirurgischen einstichstellen
WO2016020308A1 (en) * 2014-08-04 2016-02-11 Janssen Sciences Ireland Uc Compacted solid dosage form
EP3402804A1 (de) 2016-01-11 2018-11-21 Synergy Pharmaceuticals Inc. Formulierungen und verfahren zur behandlung von colitis ulcerosa

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587507A (en) * 1995-03-31 1996-12-24 Rutgers, The State University Synthesis of tyrosine derived diphenol monomers
WO1997019996A1 (en) * 1995-11-27 1997-06-05 Rutgers, The State University Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide)
WO1998036013A1 (en) * 1997-02-18 1998-08-20 Rutgers, The State University Monomers derived from hydroxy acids and polymers prepared therefrom
WO1999024107A1 (en) * 1997-11-07 1999-05-20 Rutgers, The State University Biodegradable, anionic polymers derived from the amino acid l-tyrosine
WO1999029758A1 (en) * 1997-12-12 1999-06-17 Samyang Corporation Positively-charged poly[alpha-(omega-aminoalkyl)glycolic acid] for the delivery of a bioactive agent via tissue and cellular uptake
WO1999052962A1 (en) * 1998-04-13 1999-10-21 Rutgers, The State University The construction of copolymer libraries

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
JP2002536695A (ja) * 1999-02-05 2002-10-29 エイリアン・テクノロジイ・コーポレーション アセンブリを形成するための装置および方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587507A (en) * 1995-03-31 1996-12-24 Rutgers, The State University Synthesis of tyrosine derived diphenol monomers
WO1997019996A1 (en) * 1995-11-27 1997-06-05 Rutgers, The State University Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide)
WO1998036013A1 (en) * 1997-02-18 1998-08-20 Rutgers, The State University Monomers derived from hydroxy acids and polymers prepared therefrom
WO1999024107A1 (en) * 1997-11-07 1999-05-20 Rutgers, The State University Biodegradable, anionic polymers derived from the amino acid l-tyrosine
WO1999029758A1 (en) * 1997-12-12 1999-06-17 Samyang Corporation Positively-charged poly[alpha-(omega-aminoalkyl)glycolic acid] for the delivery of a bioactive agent via tissue and cellular uptake
WO1999052962A1 (en) * 1998-04-13 1999-10-21 Rutgers, The State University The construction of copolymer libraries

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHA Y ET AL: "a one-week subdermal delivery system for l-methadone based on biodegradable microcapsules", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 7, no. 1, April 1988 (1988-04-01), pages 69 - 78, XP002143620, ISSN: 0168-3659 *

Also Published As

Publication number Publication date
JP2003519164A (ja) 2003-06-17
WO2001049249A2 (en) 2001-07-12
CA2396037A1 (en) 2001-07-12
EP1263453A2 (de) 2002-12-11
WO2001049249A3 (en) 2002-01-17
AU784226B2 (en) 2006-02-23
AU2925501A (en) 2001-07-16

Similar Documents

Publication Publication Date Title
EP1263453A4 (de) Pharmazeutische formulierung bestehend aus einem polymermatrix, zur regulierung der zeitgesteuerten freisetzung von biologisch aktiven substanzen
AU5914999A (en) Controlled release drug delivery
HUP0301242A3 (en) Controlled release drug dosage form
IL132453A0 (en) Gastroretentive controlled release microspheres for improve drug delivery
AU2180400A (en) A pharmaceutical combination for the treatment of depression
IL121275A (en) Controlled release formulation for poorly soluble basic drugs
AU5335698A (en) Pharmaceutical formulations with delayed drug release
AU7839900A (en) Reusable medication delivery device
EP1251864A4 (de) Pharmazeutische formulierung bestehend aus einer polymer-mischung und einer aktiven verbindung zur zeit-gesteuerten freisetzung
IL145581A0 (en) A modified release pharmaceutical composition comprising amoxycillin
AU4328800A (en) Pharmaceutical formulation
AU2003240654A1 (en) Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release
ZA988718B (en) Drug formulation having controlled release of active compound
IL134075A0 (en) Analgesic with controlled active substance release
AU5812800A (en) Pharmaceutical preparation
AU2773597A (en) Pharmaceutical compositions for the sustained release of insoluble active principles
AU1650401A (en) Oxadiazole derivatives and drugs containing these derivatives as the active ingredient
AU5026599A (en) A wet granulation method for preparing a stable pharmaceutical formulation
AU3669700A (en) 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
AU1650501A (en) 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
IL148543A0 (en) Pharmaceutical carrier formulation
AU7887400A (en) A slow release pharmaceutical composition
AU3839900A (en) Pharmaceutical formulation
AU6866700A (en) Biscyclopropanecarboxylic acid amide compounds and medicinal use thereof
AU1556601A (en) 1,3,4-oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020723

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

R17P Request for examination filed (corrected)

Effective date: 20020723

A4 Supplementary search report drawn up and despatched

Effective date: 20080121

17Q First examination report despatched

Effective date: 20080718

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20110207